Possible Risk Factors Associated with Relapse in Patients Treated with Neoadjuvant Chemohormonal Therapy for High Risk Prostate Cancer
Authors:
- R. S. BhattRBR. S. Bhatt
- M.M. ReganMRM.M. Regan
- Y- JYJY- J
Open Access
- 29 March 2011
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Prostate Cancer Journal
- Vol. 4 (1) , 6-13
Abstract
Possible Risk Factors Associated with Relapse in Patients Treated with Neoadjuvant Chemohormonal Therapy for High Risk Prostate CancerKeywords
This publication has 23 references indexed in Scilit:
- Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical ProstatectomyJournal of Urology, 2009
- Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical TrialJournal of Urology, 2009
- A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinomaCancer Treatment Reviews, 2009
- Neoadjuvant Platelet Derived Growth Factor Receptor Inhibitor Therapy Combined With Docetaxel and Androgen Ablation for High Risk Localized Prostate CancerJournal of Urology, 2009
- Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Before Radical Prostatectomy for Patients With High Risk Localized Prostate CancerJournal of Urology, 2008
- Neoadjuvant Chemohormonal Therapy in Poor-Prognosis Localized Prostate CancerUrology, 2008
- Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85–31International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized diseaseUrology, 2003
- NEOADJUVANT ANDROGEN ABLATION BEFORE RADICAL PROSTATECTOMY IN cT2bNxMo PROSTATE CANCER: 5-YEAR RESULTSJournal of Urology, 2002
- RANDOMIZED COMPARATIVE STUDY OF 3 VERSUS 8-MONTH NEOADJUVANT HORMONAL THERAPY BEFORE RADICAL PROSTATECTOMY: BIOCHEMICAL AND PATHOLOGICAL EFFECTSJournal of Urology, 2001